2 | IPF | ~120K in US ~110K in EU5 |
Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis (IPF). Also being advanced under the Animal Rule for medical countermeasures; plans underway to study LYT-100 in progressive fibrosing interstitial lung disease (PF-ILDs)Â as well as other fibrotic conditions where there is human data with pirfenidone suggestive of clinical benefit.
Phase completed | Phase in progress |
Deupirfenidone (LYT-100) is currently in development for the treatment of idiopathic pulmonary fibrosis (IPF), which is a rare, progressive and fatal lung disease. Deupirfenidone is a deuterated form of pirfenidone and is designed to retain the beneficial pharmacology and clinically-validated efficacy of pirfenidone but with a differentiated pharmacokinetic and tolerability profile. Deupirfenidone has demonstrated strong, consistent, and durable efficacy and a favorable tolerability profile in PureTech’s Phase 2b ELEVATE IPF clinical trial.
Deupirfenidone also has the potential to address multiple underserved diseases, including progressive fibrosing interstitial lung diseases, a group of lung diseases closely related to IPF, as well as other fibrotic conditions where there is human data with pirfenidone suggestive of clinical benefit.